Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2023-12-08 00:00:00 ET · period of report 2023-12-06 · accession 0001104659-23-124717 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-12-08 | 2023-12-06 | OLMA | Paradigm BioCapital International Fund Ltd. | 10% | P - Purchase | $11.60 | +100.0K | 6.59M | +2% | +$1.16M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2023-12-06 | P | A | 100,000 | $11.60 | 6,590,981 | I By: Paradigm BioCapital International Fund Ltd. | — | — | (F1) These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. |